CONSEQUENCES ON ECONOMIC OUTCOMES OF GENERIC VERSUS BRAND-NAME DRUGS USED IN ROUTINE CLINICAL PRACTICE: THE CASE OF TREATING PERIPHERAL NEUROPATHIC PAIN OR GENERALIZED ANXIETY DISORDER WITH PREGABALIN

被引：0

作者：

Sicras-Mainar, A.

Rejas, J. ^{[1
]}

Perez-Paramo, M. ^{[1
]}

Sanchez-Alvarez, L. ^{[2
]}

Navarro-Artieda, R. ^{[3
]}

Darba, J. ^{[4
]}

机构：

[1] Pfizer SLU, Alcobendas, Spain

[2] Primary Care Pharm, Aviles, Asturias, Spain

[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[4] Univ Barcelona, Barcelona, Spain

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.09.1891

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMU55

引用

页码：S317 / S317

页数：1

共 9 条

[1] Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
Sicras-Mainar, Antoni
Rejas-Gutierrez, Javier
Perez-Paramo, Maria
Sanchez-Alvarez, Luis
Navarro-Artieda, Ruth
Darba, Josep
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (01) : 45 - 57
[2] Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex
Navarro-Artieda, R.
Rejas-Gutierrez, J.
Perez-Paramo, M.
Sicras-Mainar, A.
[J]. NEUROLOGIA, 2018, 33 (03): : 141 - 153
[3] ECONOMIC AND PATIENT OUTCOMES OF GENERIC AND BRAND-NAME STATINS USED IN ROUTINE CLINICAL PRACTICE IN SPAIN
Sicras-Mainar, A.
Rejas, J.
Sanchez-Alvarez, L.
Navarro-Artieda, R.
Darba, J.
[J]. VALUE IN HEALTH, 2018, 21 : S451 - S451
[4] Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
Sicras-Mainar, Antoni
Rejas-Gutierrez, Javier
Navarro-Artieda, Ruth
[J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 299 - 312
[5] Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
Sicras-Mainar, A.
Sanchez-Alvarez, L.
Navarro-Artieda, R.
Darba, J.
[J]. LIPIDS IN HEALTH AND DISEASE, 2018, 17
[6] Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
A. Sicras-Mainar
L. Sánchez-Álvarez
R. Navarro-Artieda
J. Darbà
[J]. Lipids in Health and Disease, 17
[7] Pregabalin and Gabapentin in Matched Patients With Peripheral Neuropathic Pain in Routine Medical Practice in a Primary Care Setting: Findings From a Cost-Consequences Analysis in a Nested Case Control-Study
Perez, Concepcion
Navarro, Ana
Saldana, Maria T.
Masramon, Xavier
Rejas, Javier
[J]. CLINICAL THERAPEUTICS, 2010, 32 (07) : 1357 - 1370
[8] PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH NEUROPATHIC PAIN: A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL PRACTICE
Perez, C.
Navarro, A.
Saldana, M. T.
Masramon, X.
Rejas, J.
[J]. VALUE IN HEALTH, 2008, 11 (06) : A644 - A645
[9] COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: A NESTED-CASE-CONTROL ECONOMIC EVALUATION UNDER USUAL MEDICAL PRACTICE IN MENTAL HEALTH CENTERS
Alvarez, E.
Carrasco, J. L.
Olivares, J. M.
Ferro, M. B.
Perez, M.
Rejas, J.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A358 - A358

← 1 →